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As a validation study, this study addressed an under-researched area of 
bronchopulmonary cancer mortality and incidence.  The association between altitude and 
bronchopulmonary cancer mortality and incidence was investigated using data from the 
Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic 
Research.  The theoretical framework for my study was Bronfenbrenner’s ecological 
model.  This model emphasizes the relevance of social and physical environments that 
influence patterns of disease and injury and shape responses to these patterns of disease 
and injury.  The age-adjusted bronchopulmonary cancer mortality and incidence rates per 
100,000 people in the highest elevation and lowest elevation states were investigated. The 
data used in this study spans from 2006 to 2014.  In this study, bivariate statistics were 
used to analyze the data.  The relevant technique of performing an unpaired t-test was 
used.  After performing age, gender, and race-stratified analysis, no significant difference 
in cancer mortality and incidence was found within the following three groups: Black or 
African American, Asian or Pacific Islander, and American Indian or Alaska Native.  
This was a new finding, as previous studies did not stratify for race.  Cancer mortality 
and incidence were found to be lower in both the male and female groups for the highest 
elevation states.  Cancer mortality and incidence were also found to be lower in all age 
categories for the highest elevation states.  A positive social change impact of this study 
is that this research provides the groundwork for future studies to probe what in the 
environment is lowering the bronchopulmonary cancer mortality and incidence for the 
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Chapter 1: Introduction to the Study 
Introduction 
Cancer is the second leading cause of both morbidity and mortality in the world 
(World Health Organization, 2018).  In 2012 alone, there were 14 million new cases of 
cancer worldwide, and in 2015, almost 9 million people died from cancer worldwide 
(World Health Organization, 2018).  Therefore, it is important to pay attention to this 
disease and learn how to treat it because one out of every six deaths is due to cancer 
(World Health Organization, 2018).   
After reviewing the literature, I did not find any research on cancer mortality for 
site-specific cancers for people living at different altitudes in the years preceding 1982.  
However, there are studies dated 1982 and afterwards that show living at higher altitudes 
is associated with lower cancer mortality (Amsel, Waterbor, Oler, Rosenwaike, & 
Marshall, 1982; Hart, 2011; Simeonov & Himmelstein, 2015).  Amsel et al. (1982) 
analyzed age-adjusted cancer mortality data from the U.S. Department of Health, 
Education, and Welfare for 34 site-specific cancers for the period from 1950 to 1969 as 
well as for all cancer sites as a group.  They noted lower cancer mortality statistics for 
geographic counties characterized by their higher altitudes for tongue and mouth, 
esophagus, larynx, melanoma, and lung cancers as well as for all cancer sites as a group 
(Amsel et al., 1982). 
Other studies have also shown the connection between location and cancer 
mortality. Hart (2011) analyzed age-adjusted cancer mortality rates for all cancers from 
the CDC from 2001 to 2005 for the six highest elevation states versus the six lowest 
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elevation states in the United States.  He found that there was a strong association 
between low age-adjusted cancer mortality and the highest elevation states for all cancer 
sites as a group.  Additionally, Simeonov and Himmelstein (2015) used 2005 to 2009 
cancer incidence data from the Surveillance, Epidemiology, and End Results (SEER) 
Program at the National Cancer Institute (NCI) to search for an association between 
cancer incidence and altitude.  Simeonov and Himmelstein found an association between 
lower incidence of lung cancer (lung and bronchus cancers) and living at higher altitudes.  
Simeonov and Himmelstein also found a weak association between lower breast cancer 
incidence and living at high altitudes, and they found no association between prostate or 
colorectal cancers and altitude.  This finding for lung cancer is important because lung 
cancer is currently the number one cancer killer in the United States (American Lung 
Association, 2017). 
Problem Statement 
The CDC Wide-ranging Online Data for Epidemiologic Research (WONDER) 
portal captures information from 1999 through 2014.  For example, Hart (2011) explored 
the age-adjusted cancer mortality data from 2001 through 2005 using CDC WONDER 
data for all cancers as one single group.  Simeonov and Himmelstein (2015) also 
explored the age-adjusted lung cancer (lung cancer only, no bronchus cancer) incidence 
data from 2005 to 2009 using NCI data.  I investigated the association between age-
adjusted lung and bronchus cancer (from here on forward, referred to as 
bronchopulmonary cancer) mortality rates and altitude by using CDC WONDER data 
from 2006 to 2014.  I also investigated the association between age-adjusted 
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bronchopulmonary cancer incidence rates and altitude by using CDC WONDER data 
during the same period.   
My study contributes knowledge to a gap in the literature because CDC 
WONDER data from 2006 to 2014 is the continuation of the research conducted by Hart 
(2011).  In my study, I controlled for three confounders: age, sex, and race.  A positive 
social change impact of this study is that this study provides the groundwork for future 
studies to research what in the environment is causing differences in bronchopulmonary 
cancer mortality and incidence rates in the United States.   
The quantitative analysis used in my study should help in understanding the 
nature of the association and the strength of the association between altitude and 
bronchopulmonary cancer incidence and mortality rates.  In order to address the research 
questions, I measured the age-adjusted mortality rates per 100,000 people for 
bronchopulmonary cancer in the highest elevation and lowest elevation states.  I also 
measured the age-adjusted incidence rates per 100,000 people for bronchopulmonary 
cancer in the highest and lowest elevation states.  I used the same sets of highest and 
lowest elevation states that Hart (2011) had used in his study.  This will be explained in 
detail under the Operational Definitions section of this chapter.  
Purpose of the Study 
The purpose of my study was to develop the understanding of the association 
between altitude and bronchopulmonary cancer mortality and incidence by studying the 
cancer mortality data and cancer incidence data for the lowest elevation and highest 
elevation states within the United States from 2006 to 2014.  
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Research Questions and Hypotheses 
Research Question 1: Does bronchopulmonary cancer mortality differ with 
increased altitude?   
H01: There is no association between altitude and bronchopulmonary cancer 
mortality.   
H11: There is an association between altitude and bronchopulmonary cancer 
mortality.   
Research Question 2: Does bronchopulmonary cancer incidence differ with 
increased altitude?   
H02: There is no association between altitude and bronchopulmonary cancer 
incidence.   
H12: There is an association between altitude and bronchopulmonary cancer 
incidence. 
Research Objectives 
My first research objective was to answer the first central research question posed 
in my dissertation, therefore demonstrating the association between altitude and 
incidence of bronchopulmonary cancer.  The second research objective was to answer the 
second central research question posed in my dissertation, therefore demonstrating the 
association between altitude and bronchopulmonary cancer mortality.  I controlled for 
three confounders: age, sex, and race.  These risk factors were the only ones available on 




The theoretical framework for my study was Bronfenbrenner’s (1977) ecological 
model.  This model has been modified to adapt to and be applied to different scenarios 
(Satariano, 2006).  The ecological model emphasizes the relevance of social and physical 
environments that influence patterns of disease and injury and shape responses to these 
patterns of disease and injury.  The tenets of the ecological model are depicted by the 
four levels of influence used in this model, and they serve as the four central components 
of this framework.  They are the individual level, social environment, physical 
environment, and public policy components.    
At the individual level, intrapersonal traits that influence behavior are key.  The 
focus is on changing an individual’s knowledge and attitudes to influence behavior.  
Individuals who receive the information on bronchopulmonary cancer incidence and 
mortality at higher altitudes might move to higher elevation as a prophylactic against 
bronchopulmonary cancer because of their increased awareness.  The second level is the 
social environment level where interpersonal relationships between friends, colleagues, 
peers, family members, and members of the community influence behavior.  
The third level is the physical environment level whereby the environment can 
have positive or negative influences.  Using the methodology explained in the Nature of 
the Study section, I studied the age-adjusted rate per 100,000 people for 
bronchopulmonary cancer mortality in the highest elevation and lowest elevation states.  
The chosen states where I studied bronchopulmonary mortality represent the physical 
environment where positive or negative influences might occur.  It is at this third central 
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component of the physical environment that my methods and measures tie into the 
ecological model.  I used a similar methodology to study cancer incidence in the highest 
elevation and lowest elevation states.  Finally, at the public policy level, the focus is on 
changing policy to influence behavior.  Public health strategies may be implemented to 
increase awareness and understanding.  The implementation of public health strategies 
will further advance the power and the impact of the ecological model.   
Nature of Study 
I conducted a quantitative study.  The research design used in my study is an 
ecological study design.  In an ecological study, the focus is not on the individual level 
but rather on the population or group level.  The ecological study design is useful when 
measuring prevalence and incidence of disease.  It is also both observational and 
retrospective.  I retrospectively analyzed the 2006 though 2014 data from the CDC.  
Operational Definitions 
I used the same method that Hart (2011) used to determine the highest and lowest 
elevation states.  A table from the U.S. Geological Survey displaying states and their 
respective lowest and highest elevation points was used.  This is key for the internal 
validity and reliability of my study.  The highest elevation points for Delaware, 
Washington, DC, Florida, Louisiana, Mississippi, and Rhode Island are 448, 410, 345, 
535, 806, and 812 feet, respectively (U.S. Geological Survey, 2016).  This means that all 
the other points within each of these lowest elevation states are at an altitude below these 
noted highest elevation points (448, 410, 345, 535, 806, and 812 feet).  Examining the 
highest elevation points for the other 45 states reveals that their highest elevation points 
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are higher than those for Delaware, Florida, Louisiana, Mississippi, Rhode Island, and 
Washington, DC. Therefore, these six states qualify as the lowest elevation states.   
A similar methodology was used in identifying the six highest elevation states.  
The lowest elevation points for Colorado, Montana, New Mexico, South Dakota, Utah, 
and Wyoming are 3,315; 1,800; 2,842; 966; 2,000; and 3,099 feet, respectively (U.S. 
Geological Survey, 2016).  This means that the other points within each of these highest 
elevation states are at an altitude above these noted lowest elevation points (3,315; 1,800; 
2,842; 966; 2,000; and 3,099 feet).  The lowest elevation points for the other 45 states are 
lower than the lowest elevation points of Colorado, Montana, New Mexico, South 
Dakota, Utah, and Wyoming. Therefore, these six states qualify as the highest elevation 
states.   
Assumptions 
The CDC has a useful public health information portal called Wide-ranging 
Online Data for Epidemiologic Research (WONDER) (CDC, 2017) that allows the user 
to interactively request age-adjusted cancer mortality and age-adjusted cancer incidence 
data for different kinds of cancers.  This public health information portal is practical and 
interactive.  It allows someone to input qualifiers such as type of cancer, time frame of 
interest, and specific state of interest within the United States.  The age-adjusted cancer 
incidence and age-adjusted cancer mortality data in units of number of people per 
100,000 can then be requested and obtained online.  I assumed that all the data provided 
by the CDC WONDER portal are accurate, as my research results are based on the data 
from this public health information portal. 
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It was also assumed that one of the best methods to perform this study is to use 
the entire population data set of all the selected highest elevation states and lowest 
elevation states versus specific population types within the selected states.  From a 
statistical analysis point of view, I was able to harness the most amount of data from the 
CDC WONDER portal by using the entire population of the selected states.  This is the 
reason why Hart (2011) also chose to collect and analyze the data from the entire 
population of the same highest elevation and same lowest elevation states.   
Scope and Delimitations 
The specific parameters used in my study were bronchopulmonary cancer 
incidence and bronchopulmonary cancer mortality along with altitude.  My dissertation 
was focused on the association between altitude and bronchopulmonary cancer mortality 
and bronchopulmonary cancer incidence.  I closed the gap in the literature by using new 
data.  Moreover, I controlled the data for three confounders of sex, age, and race to 
observe and verify if there are differences in association for the various combinations of 
different groups.  What the scope of this dissertation does not cover is an entire list of 
possible environmental factors that may be responsible for the lower rate of 
bronchopulmonary cancer mortality and incidence in higher altitudes.  In addition to 
behavioral and lifestyle factors, there may be other responsible environmental factors 





Eighty percent of lung cancer deaths are attributed to tobacco smoking (American 
Cancer Society, 2018), though genetics are thought to be the reason why some people 
develop particular kinds of cancer.  However, genetics alone are not considered to be the 
cause of that many lung cancers (American Cancer Society, 2018).  One of the limitations 
of this study is that I did not control for smoking status, which is a behavioral and 
lifestyle factor.   
Possible environmental factors such as lower air pollution levels (Pope et al., 
2002), lower oxygen levels (Simeonov & Himmelstein, 2015), higher radiation levels 
(Scott & Di Palma, 2006), and higher vitamin D intake (Hayes, 2010) are suggested to be 
potential reasons for explaining differences in bronchopulmonary cancer incidence and 
bronchopulmonary mortality at different altitudes.  However, I did not expound on these 
potential causes of bronchopulmonary cancer incidence and cancer mortality, focusing on 
the association between altitude and bronchopulmonary cancer incidence and mortality 
for new data.  Another limitation of this study is that an association between altitude and 
bronchopulmonary cancer incidence and mortality does not imply causality or mean that 
altitude is a major influencer on bronchopulmonary cancer incidence and mortality.  
Moreover, my study does not account for lifestyle (such as tobacco use) or higher 
population densities, which lead to increased air pollution due to increased use of motor 
vehicles, watercrafts, and aircrafts.   
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Significance of the Study 
My research is a validation study conducted to address an under-researched area 
of bronchopulmonary cancer mortality and incidence.  My research design was useful for 
the findings of my research inquiry.  The results of my study provide insight concerning 
how living at different elevations is associated with different bronchopulmonary cancer 
mortality and incidence using new data for the United States.  I used the quantitative 
research design to amass new knowledge for the advancement of this area of study.   
My research inquiry is significant because it contributes to the expansion and 
development of a body of knowledge.  This study provides the groundwork for future 
studies to research what environmental factors cause differences in bronchopulmonary 
cancer mortality and incidence in the United States.  My study also contributes to positive 
social change through an ecological model.  The immediacy of the positive social change 
is brought about through the relevance of the individual component and social 
environment component of the ecological model.  Both the individual and social circles 
influence patterns of disease and injury.  The individual and social environment both 
shape responses to these patterns of disease and injury.   
At the individual level, the focus is on changing an individual’s knowledge and 
attitudes to influence behavior. Individuals may learn of the information concerning 
lower bronchopulmonary cancer incidence and mortality at higher altitudes.  They may 
relocate to higher elevation as a prophylactic against bronchopulmonary cancer due to 
their increased awareness of this issue which may bring about an immediate positive 
social change.   
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At the social environment level, interpersonal relationships between friends, 
colleagues, peers, family members, and members of the community influence behavior.  
The immediate positive social change, through the web of these interpersonal networks 
and structures, expands and impacts even more people through this social arrangement 
and framework.     
However, if individuals carry on lifestyles that are correlated with negative health 
outcomes (e.g., smoking) then the benefits of living at higher altitudes may not be able to 
counteract against the detriments of these lifestyles.  Therefore, lifestyle must be factored 
for in determining the benefits of moving to a higher elevation.   
Summary and Transition 
The CDC WONDER data that I analyzed runs from 2006 through 2014.  This 
chapter included the problem statement, purpose of the study, research questions, 
limitations of the study, and significance of the study.  The following chapter 
demonstrates an extensive review of the literature regarding cancer mortality and 





Chapter 2: Literature Review 
Introduction 
This chapter presents an overview of the research that had been done concerning 
cancer incidence and cancer mortality rates with respect to variations in altitude.  The 
primary purpose of the following literature review was to research previous studies and to 
determine a research gap in the literature that is appropriate for my study.   
Literature Review 
Using CDC data from 2001 through 2005, Hart (2011) found that for the six 
lowest elevation states in the United States, the calculated age-adjusted mean cancer 
mortality rate for all cancer sites as a group was 205 cancer deaths per 100,000 people, 
and the calculated age-adjusted mean cancer mortality rate was 171 cancer deaths per 
100,000 people for the six states with the highest altitudes.  These statistics demonstrated 
a statistically significant difference for cancer mortality between the six lowest elevation 
states and the six highest elevation states.  Hart did not discuss lung cancer incidence.  
Burtscher (2014) also indicated that residing at higher elevations is associated with lower 
mortality from stroke, cardiovascular disease, and bronchopulmonary cancer.  Simeonov 
and Himmelstein (2015) used 2005-2009 cancer incidence data from the NCI, and they 
found a strong inverse association between lung cancer incidence and altitude.  However, 
Simeonov and Himmelstein did not discuss lung cancer mortality in a similar way that 
Hart (2011) did not discuss lung cancer incidence. 
Hart (2010) also investigated the cancer mortality rates due to all cancers in low 
elevation counties in the state of Texas and compared them with the mortality rates due to 
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all cancers in high elevation counties and medium elevation counties within the same 
state.  A county with 75% or more of its terrain in the 0-250 feet above sea level range 
was classified as a low elevation county.  A county with 75% or more of its terrain in the 
1,000-2,000 feet above sea level range was classified as a medium elevation county.  
Finally, a county with 75% or more of its terrain higher than 3,000 feet above sea level 
was classified as high elevation county.  Cancer mortality due to all cancers was found to 
be statistically significant between the high and low elevation counties with a p-value of 
0.003.  Cancer mortality due to all cancers was also found to be statistically significant 
between the high and medium elevation counties with a p-value of 0.010.  Cancer 
mortality due to all cancers was not found to be statistically significant between the low 
and medium elevation counties with a p-value of 0.05.   
The final study by Hart (2013), whose investigation formed the basis of this 
study, was also focused on the association between cancer mortality and land elevation in 
American counties and cities but with another method.  In this scholarly article, he used 
median elevation data derived from the U.S. Geological Survey and the U.S. Department 
of Agriculture.  This study was concentrated on three variables that are correlated with 
elevation.  They are natural background radiation, oxygen concentration, and barometric 
pressure (Hart, 2013).  Cities and counties that were at high elevation had higher natural 
background radiation than their counterparts at low elevation.  This study showed an 
inverse correlation between natural background radiation and cancer mortality as a whole 
(not site-specific).  Cities and counties that were at high elevation had lower oxygen 
concentration and lower barometric pressure than their counterparts at low elevation.  
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This study showed direct correlation between natural background radiation and cancer 
mortality as a whole.  Whether it was the higher natural background radiation, lower 
oxygen concentration, lower barometric pressure, or a combination of the three factors 
that was responsible for the lower cancer mortality rate, was beyond the scope of this 
study.   
Winkelmayer, Hurley, Liu, and Brookhart (2012) studied the association of 
altitude with cardiovascular disease for dialysis patients in the United States.  Close to 
one million patients were followed.  All of these patients initiated dialysis sometime 
during the period of time from 1995 to 2006.  Compared to similar patients living at or 
near sea level, patients residing at altitudes greater than or equal to 6,000 feet, 
experienced a 31% decrease in myocardial infarction, a 27% decrease in strokes, and a 
19% decrease in death associated with cardiovascular disease.  
Hayes (2010) provided evidence that the enhancement of vitamin D with 
increasing altitude could explain the observed decrease in cancer rates at higher altitudes.  
Scott and Di Palma (2006) suggested that elevated diagnostic medical radiation and 
natural background radiation may lead to lower cancer mortality through the radiation 
hormesis process.  (Increased rock concentration with altitude is associated with 
increased background radiation.)  Sung et al. (2011) were the first to show in a controlled 
demonstration in mice that lower levels of oxygen delay tumorigenesis.  They were able 
to control for other confounding variables such as radiation exposure and barometric 
pressure.  Tao et al. (2000) researched cancer mortality rates from all cancers in high 
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background radiation areas of Yangjiang, China, during the period of time from 1979 
through 1995 and found that they were generally lower than in the control region.   
Danaei et al. (2005) found that the causes of bronchopulmonary cancer are 
smoking, low fruit and vegetable intake, indoor smoke from household use of solid fuels, 
and urban air pollution.  Pope et al. (2002) found that exposure over time to combustible 
air pollution can cause cardiopulmonary and lung cancer.  Samet et al. (2009) stated that 
an increased level of outdoor air pollution can be responsible for an increase in lung 
cancer incidence, however, they cannot provide a reliable estimate of risk based on the 
available data.  Subramanian and Govindan (2007) noted that an increase in cancer risk is 
associated with air pollution.  In Europe, it is estimated that 1-3.6% of lung cancer 
incidence may be associated with air pollution for the general population, and the data 
increases to 5-7% for those that never smoked.   
Cesaroni et al. (2013) studied chronic exposure to metropolitan air pollution and 
its effect on mortality.  The study used a cohort of greater than one million adult subjects 
in Rome, Italy.  In particular, Cesaroni et al. (2013) investigated the causal relationship 
between nitrogen dioxide and fine particulate matter to mortality.  They were able to 
assess the concentration-response relationship.  The most robust relationship was 
established for cardiac ischemia.  It was then followed by cardiovascular illness and lung 
cancer.  The results of this study will have a profound effect on the next wave of policy 
changes regarding air quality in the European Union.   
Siegel, Ma, Zou, and Jemal (2014) stated that even though cancer mortality has 
been on the decline for the last two decades, further social positive change can be 
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accelerated by reinforcing existing cancer control knowledge to the population especially 
to those with low socioeconomic status. 
Information from by the Lung Institute provides biological reasons why it may be 
beneficial to live at higher altitudes.  At higher elevations, the lungs expand compared to 
lower elevations.  The expansion allows the lungs to contribute more to beneficial body 
functions and processes.  The lung expansion enables the body to produce more red blood 
cells which are essential in promoting good health.  More capillaries are produced which 
allows the lungs to efficiently bring oxygen to the cardiovascular system (Lung Institute, 
2016).   
Research Gap in the Literature 
The CDC WONDER data that I have analyzed runs from 2006 through 2014.  I 
have investigated the age-adjusted cancer mortality phenomenon further by using more 
current CDC data starting where Hart had left off in 2005.  I have investigated the age-
adjusted cancer incidence phenomenon by using CDC data to compare with the 2005 to 
2009 NCI data used by Simeonov and Himmelstein (2015).  These two items that have 
been investigated comprise the identified research gap in the literature.  
Theoretical Foundation 
The theoretical framework for my study is Bronfenbrenner’s (1977) ecological 
model. This model has since been modified over time in order to adapt to and be applied 
to different scenarios (Satariano, 2006).  The ecological model emphasizes four 
components that greatly influence patterns of disease and injury and strongly shape our 
responses to these patterns of disease and injury.  The tenets of the ecological model are 
17 
 
depicted by the four levels of influence used in this model, and they serve as the four 
central components of this framework.  They are the individual level, social environment, 
physical environment, and public policy components.    
At the individual level, intrapersonal traits that influence behavior are key.  The 
focus is on changing an individual’s knowledge and attitudes to influence behavior.  
Characteristics of this first level are personal knowledge, demographics, beliefs, values, 
aptitude, conduct, self-awareness, and self-respect.  Individuals may learn of the 
information on lower bronchopulmonary cancer incidence and mortality at higher 
altitudes. On processing the information, they might move to higher elevation as a 
prophylactic against bronchopulmonary cancer because of their increased awareness.  
They simply may just want to seek an environment for themselves that are conducive to 
great health benefits.   
The second level is the social environment level where interpersonal relationships 
between friends, colleagues, peers, family members, and members of the community 
influence behavior.  Characteristics of this second level are social structure, social 
foundation, family structure, work structure, neighborhood network, friendship network, 
and peer structure. 
The third level is the physical environment level whereby the environment can 
have positive or negative influences.  Characteristics of this third level are climate, 
habitat, setting, situation, ambiance, elevation, and terrain.  I have studied the age-
adjusted rate per 100,000 people for bronchopulmonary cancer mortality and 
bronchopulmonary cancer incidence in the highest elevation and lowest elevation states.  
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The chosen states where I have studied the bronchopulmonary mortality and incidence 
represent the physical environment where positive or negative influences might occur.  It 
is at this third central component of the physical environment that my methods and 
measures tie into the ecological model.  Individuals tend to avoid an environment where 
they may be susceptible to maladies such as cancer.  This may possibly include relocating 
from a low elevation environment to a high elevation environment in order to harness any 
health benefits.   
Finally, at the public policy level, the focus is on changing policy in order to 
influence behavior.  Public health strategies may be implemented to increase awareness 
and understanding.  Characteristics of this fourth level are regulations, protocols, tariffs, 
government agencies, and codes.  Without the implementation of public health strategies, 
it may be difficult to witness the power and impact of the ecological model.  These multi-
level interventions are theorized to be very effective in bringing forth a positive social 
change impact leading to a better tomorrow with positive health outcomes.  
Summary 
In Chapter 2, I performed the literature review of my research topic and then 
identified a research gap in the literature.  I also described the theoretical foundation of 
my research.  In Chapter 3, I will discuss the research methods and statistical analysis 




Chapter 3: Research Method 
Introduction 
This chapter consists of a description of my research methodology.  The four 
main parts of my methodology are research design, sampling, collection of data, and 
analysis of data.  The description of the research design explains why I selected this study 
design.  I illustrate what was involved in the sampling process.  Finally, I also delineate 
the entire data collection process concluding with a comprehensive analysis of the data in 
my study.  
Research Questions 
Research Question 1: Does bronchopulmonary cancer mortality differ with 
increased altitude?   
H01: There is no association between altitude and bronchopulmonary cancer 
mortality.   
H11: There is an association between altitude and bronchopulmonary cancer 
mortality.   
Research Question 2: Does bronchopulmonary cancer incidence differ with 
increased altitude?   
H02: There is no association between altitude and bronchopulmonary cancer 
incidence.   




Design of the Study 
The goal of my research design was to make sure that the data collected allowed 
me to effectively and systematically answer my research questions.  Obtaining data that 
was specific to my research questions required that I understand the significance of an 
observable phenomenon, which would justify my study design.  The research design used 
in my study is an ecological study design with a quantitative approach.  It is also both 
observational and retrospective.  The quantitative analysis used in my study helped to 
understand the nature of the association and the extent of the association between altitude 
and bronchopulmonary cancer mortality and incidence.  Being able to better understand 
the association between altitude and bronchopulmonary cancer incidence and mortality 
rates is one of the strengths of my study design.  This same study design has a weakness 
in that it does not help establish causality.  
Original Study Design   
Hart (2011) identified the six highest elevation states in his article to be Colorado, 
Montana, New Mexico, South Dakota, Utah, and Wyoming.  He also identified the six 
lowest elevation states to be Delaware, Florida, Louisiana, Mississippi, Rhode Island, and 
Washington, DC.  I used the same method that Hart used to determine the highest and 
lowest elevation states using a table from the U.S. Geological Survey displaying states 
and their respective lowest and highest elevation points.  The highest elevation points for 
Delaware, Florida, Louisiana, Mississippi, Rhode Island, and Washington, DC are 448, 
345, 535, 806, 812, and 410 feet respectively (U.S. Geological Survey, 2016).  This 
means that all of the other points within each of these lowest elevation states are at an 
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altitude below these noted highest elevation points. The highest elevation points for other 
states were all higher than the highest elevation points of these six states, making them 
the six lowest elevation states. 
A similar methodology was used in identifying the six highest elevation states.  
The lowest elevation points for Colorado, Montana, New Mexico, South Dakota, Utah, 
and Wyoming are 3315, 1800, 2842, 966, 2000, and 3099 feet respectively (U.S. 
Geological Survey, 2016).  This means that all of the other points within each of these 
highest elevation states are at an altitude above these noted lowest elevation points (3315, 
1800, 2842, 966, 2000, and 3099 feet).  The lowest elevation points for other states were 
all lower than the lowest elevation points of these six states, making them the six highest 
elevation states. 
My study contributes knowledge to the research gap in the literature because I 
analyzed new data from the CDC ranging from 2006 to 2014.  I controlled for three 
possible confounders of age, sex, and race, which had not been done previously.   
Sampling   
My research involves the entire population of six states that have been selected as 
highest elevation states and the entire population of six states that have been selected as 
lowest elevation states.  Therefore, the sample population used in my study is the entire 
population of these chosen states.   
Data Sources and Variables  
I used secondary data from the CDC in my study.  This study was focused on the 
2006 through 2014 age-adjusted cancer incidence data and the 2006 through 2014 age-
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adjusted cancer mortality rates from the CDC.  The independent variables used are the 
names of the six highest elevation states and the names of the six lowest elevations.  The 
dependent variables are bronchopulmonary cancer incidence rates and bronchopulmonary 
cancer mortality rates. 
Data Collection  
The CDC has a very useful public health information portal called WONDER 
(CDC, 2017) that allows the user to interactively request age-adjusted cancer incidence 
and age-adjusted cancer mortality data for different kinds of cancers.  This public health 
information portal is very practical and interactive.  One can input qualifiers such as type 
of cancer, time frame of interest, and specific state of interest within the United States.  
The age-adjusted cancer incidence and age-adjusted cancer mortality data in units of 
number of people per 100,000 can then be requested and obtained online. 
The CDC WONDER portal captures information from 2006 through 2014.  Hart 
(2011) used CDC data from 2001 through 2005 and found a statistically significant 
difference for cancer mortality between the six lowest elevation states and the six highest 
elevation states within the U.S.  I have investigated the age-adjusted cancer mortality 
phenomenon further by starting where Hart had stopped in 2005 by researching the CDC 
bronchopulmonary cancer mortality data from 2006 through 2014.  Simeonov and 
Himmelstein (2015) used 2005-2009 cancer incidence data from the NCI, and they found 
a very strong inverse association between lung cancer incidence and altitude.  I also have 
investigated the age-adjusted cancer incidence phenomenon by using the CDC lung and 
bronchus cancer incidence data from 2006 through 2014.   
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Data Analysis  
The purpose of my study is to further develop the understanding of the association 
between altitude and bronchopulmonary cancer mortality and incidence by studying the 
bronchopulmonary cancer mortality data and the bronchopulmonary cancer incidence 
data for the highest elevation and lowest elevation states within the United States from 
2006 to 2014.  I have controlled for 3 confounders of age, sex, and race as they were the 
only risk factor that were available on the CDC WONDER.  Even the CDC data are all 
age-adjusted, I still further stratified my analysis by age, using 3 different age groups, to 
detect any significant differences in cancer mortality and incidence within each age group 
for the highest and elevation states.   
In this study, bivariate statistics were used to analyze the data.  The relevant 
technique of performing an unpaired t-test was used.  The independent variables are the 
names of the six highest elevation states and the names of the six lowest elevations.  The 
dependent variables are bronchopulmonary cancer incidence rates and bronchopulmonary 
cancer mortality rates. 
This test contrasts the disparity between the two selected categories of elevation 
states.  The company GraphPad Software has a software application that is perfectly 
suitable for analyzing my data (GraphPad, 2018).  The software is called “Quick Calcs 
Online Calculator for Scientists.”  I used this calculator in this study to calculate the p-
value resulting from the comparison between these two groups of data using the t-test.  
The age-adjusted cancer incidence rates per 100,000 from the six highest elevation states 
from 2006-2014 were investigated.  They were compared to the age-adjusted cancer 
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incidence rate per 100,000 from the six lowest elevation states during the same period 
from 2006-2014.  I controlled for the 3 confounders age, sex, and race.   
The null hypothesis related to my first research question is that there is no 
difference between the bronchopulmonary cancer mortality rates from the highest 
elevation states when compared to the bronchopulmonary cancer mortality rates from the 
lowest elevation states.  The alternative hypothesis is that there is a statistically 
significant difference between the two groups of cancer mortality. If the p-value is less 
than 0.05, then the null hypothesis should be rejected.  With the null hypothesis 
dismissed, the alternative hypothesis is then applicable to the results of the study.  It 
should be more completely stated as the observed difference between bronchopulmonary 
cancer mortality from the highest elevation states and the bronchopulmonary cancer 
mortality from the lowest elevation states, is statistically significant (Gertsman, 2008).  
Bivariate statistics were used again to analyze the data for cancer incidence.  The 
age-adjusted cancer incidence rates per 100,000 from the six highest elevation states from 
2006-2014 were investigated.  They were compared to the age-adjusted cancer incidence 
rates per 100,000 from the six lowest elevation states during the same period from 2006-
2014.  I also controlled for the 3 confounders of age, sex, and race.   
The null hypothesis related to my second research question is that there is no 
difference between the bronchopulmonary cancer incidence rates from the highest 
elevation states when compared to the bronchopulmonary cancer incidence rates from the 
lowest elevation states.  The alternative hypothesis is that there is a statistically 
significant difference between the two groups of cancer incidence.  If the p-value is less 
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than 0.05, then the null hypothesis should be rejected.  With the null hypothesis 
dismissed, the alternative hypothesis is then applicable to the results of the study.  It 
should be more completely stated as the observed difference between bronchopulmonary 
cancer incidence from the highest elevation states and the bronchopulmonary incidence 
from the lowest elevation states, is statistically significant (Gertsman, 2008).   
Summary  
The research design associated with my study, sampling, collection of data, and 
analysis of data are described in this chapter.  The research design used in my study is an 
ecological study design.  It is also both observational and retrospective.  It takes a 
quantitative approach as data from the CDC WONDER public health information portal 
is used to further develop the understanding of the association between altitude and 
bronchopulmonary cancer mortality and incidence by studying the cancer mortality data 
and cancer incidence data for the lowest elevation and highest elevation states within the 
United States from 2006 to 2014.  The data was controlled for age, sex, and race.   
The bivariate statistical technique of conducting an unpaired t-test is used to 
analyze the data in this study.  This test compares the difference between the 
bronchopulmonary cancer mortality of the two groups of elevation states in order to 
determine a p-value which allows for the scientific rejection of the null hypothesis if 
there is a statistically significant difference between the two groups.  It also compares the 
difference between the bronchopulmonary cancer incidence of the two groups of 
elevation states in order to determine a p-value which allows for the scientific rejection of 
26 
 
the null hypothesis.  This brings a conclusion to my proposal.  The next section, Chapter 





Chapter 4: Results  
Introduction 
My purpose in conducting this quantitative, observational, retrospective 
ecological study, was to measure the association between altitude and bronchopulmonary 
cancer.  This study was also undertaken to answer the following two research questions: 
Research Question 1: Does bronchopulmonary cancer mortality differ with 
increased altitude?   
Research Question 2: Does bronchopulmonary cancer incidence differ with  
increased altitude?   
In this chapter, I describe the process of collecting secondary data from the CDC. 
I include an explanation of the sample population that is used in my study.  Lastly, I 
illustrate my data analysis well-defined tables.   
Data Collection 
I received Walden University’s Institutional Review Board (IRB) approval to 
conduct this study on October 17, 2017 (approval number 10-17-17-0074351).  I used the 
secondary from the CDC public health information portal called WONDER (CDC, 
2017).  This public health information portal allows the user to interactively request age-
adjusted cancer incidence and age-adjusted cancer mortality data for different kinds of 
cancers.  I collected data on bronchopulmonary cancer.   
The CDC WONDER portal captures information from 2006 through 2014.  Hart 
(2011) used CDC data from 2001 through 2005 and found a statistically significant 
difference for cancer mortality between the six lowest elevation states and the six highest 
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elevation states within the United States.  The six lowest elevation states are Delaware, 
Florida, Louisiana, Mississippi, Rhode Island, and Washington, DC.  The six highest 
elevation states are Colorado, Montana, New Mexico, South Dakota, Utah, and 
Wyoming.  I further investigated the association between altitude and cancer mortality by 
researching the CDC bronchopulmonary cancer mortality data from 2006 through 2014, 
which is the time right after the time studied by Hart.  Additionally, Simeonov and 
Himmelstein (2015) used 2005-2009 cancer incidence data from the NCI and found a 
strong inverse association between lung cancer incidence and altitude.  Therefore, I also 
investigated the association between altitude and cancer incidence by using the CDC 
bronchopulmonary cancer incidence data from 2006 through 2014.   
Sample Population 
The sample population used in my study is the entire population of chosen states 
selected to represent the lowest elevation states and the highest elevation states.  My 
research involves the entire population of six states that have been selected as the highest 
elevation states and the entire population of six states that have been selected as the 
lowest elevation states.  
Controlling for Possible Confounders 
In addition to continuing the work conducted by Hart (2011) and Simeonov and 
Himmelstein (2015), I elevated this research study by controlling for possible risk factors 
such as age, sex, and race.  I categorized the entire population of each chosen state 
according the following age range: 44 years and younger, 45-64 years, and 65 years and 
older.  For sex, I divided the entire population of each chosen state into the male and 
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female genders.  Finally, I divided the entire population each chosen state into four 
categories of race: White, Black or African American, Asian or Pacific Islander, and 
American Indian or Alaska Native.    
Results for Cancer Mortality 
Female Cancer Mortality 
The age-adjusted cancer mortality rates per 100,000 for the six highest elevation 
states from 2006-2014 are displayed in Table 1 for the entire female population in those 
states.  They are compared to the entire female, age-adjusted cancer mortality rate per 
100,000 for the six lowest elevation states during the same period.  
Table 1 
 
Female Bronchopulmonary Cancer Mortality, 2006-2014 
 
 
Deaths Population Age-adjusted mortality rate per 
100,000  
Highest elevation states    
Colorado 6,898 22,615,514 29.5 
Montana 2,229 4,437,389 38.6 
New Mexico 3,006 9,304,585 27.3 
South Dakota 1,633 3,671,332 34.8 
Utah 1,672 12,342,595 16.3 
Wyoming 961 2,472,442 34.4 
Totals 16,399 54,843,857 28.3 
Lowest elevation states    
Delaware 2,372  4,173,344 44.9 
Washington, DC 1,056 2,891,757 34.6 
Florida 47,180 87,155,387 37.0 
Louisiana 10,054 20,757,395 42.5 
Mississippi 6,682 13,712,010 41.5 
Rhode Island 2,736 4,905,070 42.2 




Male Cancer Mortality 
The age-adjusted cancer mortality rates per 100,000 for the six highest elevation 
states from 2006-2014 are displayed in Table 2 for the entire male population in those 
states.  They are compared to the entire male, age-adjusted cancer mortality rate per 
100,000 for the six lowest elevation states during the same period.  
Table 2  
 
Male Bronchopulmonary Cancer Mortality, 2006-2014 
 Deaths Population Age-adjusted mortality 
rate per 100,000 
Highest elevation states    
Colorado 7,442 22,756,887 39.8 
Montana 2,483 4,471,606 49.5 
New Mexico 3,622 9,095,302 40.5 
South Dakota 2,244 3,683,308 58.2 
Utah 2,246 12,463,500 25.8 
Wyoming 1,120 2,567,794 45.7 
Totals 19,157 55,038,397 40.2 
Lowest elevation states    
Delaware 2,678 3,919,404 64.3 
Washington, DC 1,221 2,596,108 56.1 
Florida 59,903 83,366,874 57.5 
Louisiana 14,212 19,848,574 76.6 
Mississippi 10,884 12,946,292 88.7 
Rhode Island 2,970 4,589,221 62.2 
Totals 91,868 127,266,473 62.8 
 
Ages 44 and Younger Cancer Mortality 
The age-adjusted cancer mortality rates per 100,000 for the six highest elevation 
states from 2006-2014 are displayed in Table 3 for the entire ages 44 and younger 
population in those states.  They are compared to the entire ages 44 and younger, age-






Ages 44 and Younger Bronchopulmonary Cancer Mortality, 2006-2014 
 
 
Deaths Population Age-adjusted mortality rate per 
100,000  
Highest elevation states    
Colorado 118 23,382,087 0.5 
Montana 27 5,019,498 0.6 
New Mexico 45 11,091,784 0.5 
South Dakota 20 4,377,849 0.5 
Utah 50 17,622,464 0.4 
Wyoming 18 3,011,736 0.7 
Totals 278 69,505,418 0.5 
Lowest elevation states    
Delaware 49  4,723,070 1.1 
Washington, DC 22 3,598,013 0.7 
Florida 938 95,079,789 1.0 
Louisiana 291 24,952,570 1.4 
Mississippi 216 16,393,233 1.5 
Rhode Island 71 5,498,392 1.4 
Totals 1,587 150,245,067 1.1 
 
Ages 45 to 64 Cancer Mortality 
The age-adjusted cancer mortality rates per 100,000 for the six highest elevation 
states from 2006-2014 are displayed in Table 4 for the entire ages 45 to 64 population in 
those states.  They are compared to the entire ages 45 to 64, age-adjusted cancer mortality 









Ages 45 to 64 Bronchopulmonary Cancer Mortality, 2006-2014 
 
 
Deaths Population Age-adjusted mortality rate per 
100,000  
Highest elevation states    
Colorado 3,659 11,898,006 28.4 
Montana 1,116 2,543,993 38.7 
New Mexico 1,480 4,812,297 27.4 
South Dakota 941 1,911,295 44.5 
Utah 1,101 4,897,551 21.0 
Wyoming 511 1,366,558 32.9 
Totals 8,808 27,449,700 29.2 
Lowest elevation states    
Delaware 1,381 2,178,521 58.2 
Washington, DC 769 1,264,262 56.5 
Florida 26,826 45,451,086 53.6 
Louisiana 7,737 10,553,092 68.0 
Mississippi 5,612 6,779,579 76.4 
Rhode Island 1,485 2,606,142 53.0 
Totals 43,810 68,832,682 58.2 
 
Ages 65 and Older Cancer Mortality 
The age-adjusted cancer mortality rates per 100,000 for the six highest elevation 
states from 2006-2014 are displayed in Table 5 for the entire ages 65 and older 
population in those states.  They are compared to the entire ages 65 and older, age-
adjusted cancer mortality rate per 100,000 for the six lowest elevation states during the 








Ages 65 and Older Bronchopulmonary Cancer Mortality, 2006-2014 
 
 
Deaths Population Age-adjusted mortality rate per 
100,000  
Highest elevation states    
Colorado 10,563 5,092,308 216.1 
Montana 3,569 1,345,504 272.5 
New Mexico 5,103 2,495,806 211.5 
South Dakota 2,916 1,065,496 273.4 
Utah 2,767 2,286,080 124.3 
Wyoming 1,552 641,942 249.8 
Totals 26,470 12,927,136 211.1 
Lowest elevation states    
Delaware 3,620 1,191,157 312.4 
Washington, DC 1,486 655,590 242.1 
Florida 79,319 29,991,386 265.6 
Louisiana 16,238 5,100,307 325.0 
Mississippi 11,738 3,485,490 343.9 
Rhode Island 4,150 1,389,757 296.8 
Totals 116,551 41,783,687 281.5 
 
White Cancer Mortality 
The age-adjusted cancer mortality rates per 100,000 for the six highest elevation 
states from 2006-2014 are displayed in Table 6 for the entire White population in those 
states.  They are compared to the entire White, age-adjusted cancer mortality rate per 









White Bronchopulmonary Cancer Mortality, 2006-2014 
 
 
Deaths Population Age-adjusted mortality rate per 
100,000  
Highest elevation states    
Colorado 13,518 40,787,703 34.1 
Montana 4,483 8,138,562 42.9 
New Mexico 6,328 15,560,336 34.7 
South Dakota 3,635 6,444,469 44.0 
Utah 3,766 23,162,746 20.6 
Wyoming 2,032 4,769,629 39.5 
Totals 33,762 98,863,445 33.7 
Lowest elevation states    
Delaware 4,285 5,906,272 54.3 
Washington, DC 476 2,316,627 27.6 
Florida 97,978 135,813,917 47.5 
Louisiana 17,524 26,295,358 56.1 
Mississippi 12,663 16,204,647 61.6 
Rhode Island 5,495 8,310,100 51.4 
Totals 138,421 194,846,921 49.7 
 
Black or African American Cancer Mortality 
The age-adjusted cancer mortality rates per 100,000 for the six highest elevation 
states from 2006-2014 are displayed in Table 7 for the entire Black or African American 
population in those states.  They are compared to the entire Black or African American, 
age-adjusted cancer mortality rate per 100,000 for the six lowest elevation states during 
the same period.  The data for Montana, South Dakota, and Wyoming are suppressed by 
the CDC because the absolute number of bronchopulmonary cancer mortality cases for 
Black or African Americans are extremely low because the Black or African American 
population in those states are very low.  This was done to protect the identity of the 
people involved since it may be relatively easy to guess who they are (CDC, 2017).  
Going forward, there will be suppressed data in some more tables for the same reason.  
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However, the totals in each table reflect the total number of deaths for the entire table, 
which indicate how many deaths there had been in each of the individual states.   
Table 7 
 
Black or African American Bronchopulmonary Cancer Mortality, 2006-2014 
 
 
Deaths Population Age-adjusted mortality rate per 
100,000  
Highest elevation states    
Colorado 529 2,219,493 40.1 
Montana Suppressed 68,946 Suppressed 
New Mexico 133 519,423 40.9 
South Dakota Suppressed 130,948 Suppressed 
Utah 41 379,072 33.9 
Wyoming Suppressed 75,330 Suppressed 
Totals 734 3,393,212 38.9 
Lowest elevation states    
Delaware 711 1,838,424 49.9 
Washington, DC 1,774 2,909.549 53.8 
Florida 8,234 28,864,160 37.7 
Louisiana 6,570 13,270,198 61.2 
Mississippi 4,831 10,022,814 61.0 
Rhode Island 151 763,987 33.5 
Totals 22,271 57,669,132 48.7 
 
Asian or Pacific Islander Cancer Mortality 
The age-adjusted cancer mortality rates per 100,000 for the six highest elevation 
states from 2006-2014 are displayed in Table 8 for the entire Asian or Pacific Islander 
population in those states.  They are compared to the entire Asian or Pacific Islander, 
age-adjusted cancer mortality rate per 100,000 for the six lowest elevation states during 








Asian or Pacific Islander Bronchopulmonary Cancer Mortality, 2006-2014 
 
 
Deaths Population Age-adjusted mortality rate per 
100,000  
Highest elevation states    
Colorado 206 1,553,745 22.1 
Montana Suppressed 76,279 Suppressed 
New Mexico 53 342,929 20.9 
South Dakota Suppressed 86,195 Suppressed 
Utah 85 854,164 20.1 
Wyoming Suppressed 52,930 Suppressed 
Totals 372 2,966,242 21.8 
Lowest elevation states    
Delaware 36 291,937 22.9 
Washington, DC 24 225,590 20.2 
Florida 736 4,945,089 20.2 
Louisiana 118 719,583 27.6 
Mississippi 50 274,769 34.0 
Rhode Island 42 326,711 24.6 
Totals 1,006 6,783,679 21.6 
 
American Indian or Alaska Native Cancer Mortality 
The age-adjusted cancer mortality rates per 100,000 for the six highest elevation 
states from 2006-2014 are displayed in Table 9 for the entire American Indian or Alaska 
Native population in those states.  They are compared to the entire American Indian or 
Alaska Native, age-adjusted cancer mortality rate per 100,000 for the six lowest elevation 








American Indian or Alaskan Native Bronchopulmonary Cancer Mortality, 2006-2014 
 
 
Deaths Population Age-adjusted mortality rate per 
100,000  
Highest elevation states    
Colorado 87 811,460 23.7 
Montana 207 625,208 63.9 
New Mexico 114 1,977,199 9.5 
South Dakota 222 693,028 75.7 
Utah 26 410,113 17.6 
Wyoming 32 142,347 52.0 
Totals 688 4,659,335 28.2 
Lowest elevation states    
Delaware 18 56,115 51.4 
Washington, DC Suppressed 36,099 Suppressed 
Florida 135 899,095 20.5 
Louisiana 54 320,830 25.4 
Mississippi 22 156,072 21.7 
Rhode Island 18 93,493 34.7 
Totals 250 1,561,704 23.5 
 
All non-White Cancer Mortality 
Since all of the data for the non-White races demonstrated no significant 
difference between the highest elevation states and the lowest elevations states, it is 
imperative that we sum up the cancer mortality data from the three races of Black or 
African American, Asian or Pacific Islander, and American Indian or Alaska Native, to 
see if the summed data still show no statistically significant difference between the 
highest elevation states and the lowest elevations states. 
The age-adjusted cancer mortality rates per 100,000 for the six highest elevation 
states from 2006-2014 are displayed in Table 10 for the entire non-White population in 
those states.  They are compared to the entire non-White, age-adjusted cancer mortality 
rate per 100,000 for the six lowest elevation states during the same period.  As it is 
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noticeable in the following table, there is no suppressed data, because of the higher 
cancer mortality statistics collected. 
Table 10 
 
All Non-White Bronchopulmonary Cancer Mortality, 2006-2014 
 
 
Deaths Population Age-adjusted mortality rate per 
100,000  
Highest elevation states    
Colorado 822 4,584,698 31.1 
Montana 229 770,433 58.4 
New Mexico 300 2,839,551 16.7 
South Dakota 242 910,171 65.0 
Utah 152 1,643,349 21.8 
Wyoming 49 270,607 34.7 
Totals 1,794 11,018,809 29.6 
Lowest elevation states    
Delaware 765 2,186,476 46.5 
Washington, DC 1,801 3,171,238 52.3 
Florida 9,105 34,708,344 34.6 
Louisiana 6,742 14,310,611 59.0 
Mississippi 4,903 10,453,655 60.0 
Rhode Island 211 1,184,191 31.2 
Totals 23,527 66,014,515 45.3 
 
Results for Cancer Incidence 
Female Cancer Incidence 
The age-adjusted cancer incidence rates per 100,000 for the six highest elevation 
states from 2006-2014 are displayed in Table 11 for the entire female population in those 
states.  They are compared to the entire female, age-adjusted cancer incidence rate per 





Female Bronchopulmonary Cancer Incidence, 2006-2014 
 
 
Cases Population Age-adjusted incidence rate per 
100,000  
Highest elevation states    
Colorado 10,068 22,615,514 43.0 
Montana 3,177 4,437,389 55.4 
New Mexico 4,089 9,304,585 37.2 
South Dakota 2,263 3,671,332 49.6 
Utah 2,435 12,342,595 23.7 
Wyoming 1,265 2,472,442 44.8 
Totals 23,297 54,843,857 40.2 
Lowest elevation states    
Delaware 3,400 4,173,344 64.7 
Washington, DC 1,467 2,891,757 49.0 
Florida 68,796 87,155,387 55.1 
Louisiana 13,390 20,757,395 56.6 
Mississippi 9,052 13,712,010 56.5 
Rhode Island 4,054 4,905,070 64.4 
Totals 100,159 133,594,963 56.0 
 
Male Cancer Incidence 
The age-adjusted cancer incidence rates per 100,000 for the six highest elevation 
states from 2006-2014 are displayed in Table 12 for the entire male population in those 
states.  They are compared to the entire male, age-adjusted cancer incidence rate per 









Male Bronchopulmonary Cancer Incidence, 2006-2014 
 
 
Cases Population Age-adjusted incidence rate per 
100,000  
Highest elevation states    
Colorado 10,024 22,756,887 52.0 
Montana 3,313 4,471,606 65.2 
New Mexico 4,617 9,095,302 50.2 
South Dakota 2,831 3,683,308 72.8 
Utah 2,992 12,463,500 33.7 
Wyoming 1,349 2,567,794 53.0 
Totals 25,126 55,038,397 51.5 
Lowest elevation states    
Delaware 3,632 3,919,404 86.0 
Washington, DC 1,632 2,596,108 72.4 
Florida 79,155 83,366,874 75.7 
Louisiana 18,043 19,848,574 94.9 
Mississippi 13,575 12,946,292 107.7 
Rhode Island 3,955 4,589,221 82.2 
Totals 119,992 127,266,473 81.3 
 
Ages 44 and Younger Cancer Incidence 
The age-adjusted cancer incidence rates per 100,000 for the six highest elevation 
states from 2006-2014 are displayed in Table 13 for the entire ages 44 and younger 
population in those states.  They are compared to the entire ages 44 and younger, age-
adjusted cancer incidence rate per 100,000 for the six lowest elevation states during the 








Ages 44 and Younger Bronchopulmonary Cancer Incidence, 2006-2014 
 
 
Cases Population Age-adjusted incidence rate per 
100,000  
Highest elevation states    
Colorado 281 28,382,087 1.1 
Montana 76 5,019,498 1.7 
New Mexico 101 11,091,784 1.1 
South Dakota 47 4,377,849 1.3 
Utah 117 17,622,464 0.9 
Wyoming 30 3,011,736 1.1 
Totals 652 69,505,418 1.1 
Lowest elevation states    
Delaware 109 4,723,070 2.5 
Washington, DC 63 3,598,013 2.1 
Florida 1,882 95,079,789 2.1 
Louisiana 524 24,952,570 2.4 
Mississippi 343 16,393,233 2.5 
Rhode Island 122 5,498,392 2.3 
Totals 3,043 150,245,067 2.2 
 
Ages 45 to 64 Cancer Incidence 
The age-adjusted cancer incidence rates per 100,000 for the six highest elevation 
states from 2006-2014 are displayed in Table 14 for the entire ages 45 to 64 population in 
those states.  They are compared to the entire ages 45 to 64, age-adjusted cancer 









Ages 45 to 64 Bronchopulmonary Cancer Incidence, 2006-2014 
 
 
Cases Population Age-adjusted incidence rate per 
100,000  
Highest elevation states    
Colorado 5,836 11,898,006 45.4 
Montana 1,706 2,543,993 59.3 
New Mexico 2,307 4,812,297 43.0 
South Dakota 1,410 1,911,295 67.3 
Utah 1,680 4,897,551 32.1 
Wyoming 797 1,386,558 51.4 
Totals 13,736 27,449,700 45.8 
Lowest elevation states    
Delaware 2,117 2,178,521 89.5 
Washington, DC 1,190 1,264,262 87.3 
Florida 41,806 45,451,086 83.9 
Louisiana 11,068 10,553,092 97.4 
Mississippi 7,986 6,779,579 108.9 
Rhode Island 2,421 2,606,142 86.5 
Totals 66,588 68,832,682 88.7 
 
Ages 65 and Older Cancer Incidence 
The age-adjusted cancer incidence rates per 100,000 for the six highest elevation 
states from 2006-2014 are displayed in Table 15 for the entire ages 65 and older 
population in those states.  They are compared to the entire ages 65 and older, age-
adjusted cancer incidence rate per 100,000 for the six lowest elevation states during the 









Ages 65 and Older Bronchopulmonary Cancer Incidence, 2006-2014 
 
 
Cases Population Age-adjusted incidence rate per 
100,000  
Highest elevation states    
Colorado 13,975 5,092,308 284.8 
Montana 4,708 1,345,504 358.6 
New Mexico 6,298 2,495,806 259.1 
South Dakota 3,637 1,065,496 346.0 
Utah 3,630 2,286,080 162.2 
Wyoming 1,787 641,942 286.2 
Totals 34,035 12,927,136 270.7 
Lowest elevation states    
Delaware 4,806 1,191,157 413.4 
Washington, DC 1,846 625,590 301.2 
Florida 104,263 29,991,386 350.7 
Louisiana 19,841 5,100,307 394.9 
Mississippi 14,298 3,485,490 415.9 
Rhode Island 5,466 1,389,757 400.8 
Totals 150,520 41,783,687 364.4 
 
White Cancer Incidence 
The age-adjusted cancer incidence rates per 100,000 for the six highest elevation 
states from 2006-2014 are displayed in Table 16 for the entire White population in those 
states.  They are compared to the entire White, age-adjusted cancer incidence rate per 









White Bronchopulmonary Cancer Incidence, 2006-2014 
 
 
Cases Population Age-adjusted incidence rate per 
100,000  
Highest elevation states    
Colorado 18,867 40,787,703 46.9 
Montana 6,057 8,138,562 57.9 
New Mexico 8,272 15,560,336 45.0 
South Dakota 4,754 6,444,469 58.4 
Utah 5,178 23,162,746 27.9 
Wyoming 2,549 4,769,629 48.6 
Totals 45,677 98,863,445 45.2 
Lowest elevation states    
Delaware 5,926 5,906,272 75.2 
Washington, DC 651 2,316,627 36.9 
Florida 134,191 135,813,917 66.0 
Louisiana 22,724 26,295,358 72.4 
Mississippi 16,387 16,204,647 79.3 
Rhode Island 7,640 8,310,100 72.6 
Totals 187,519 194,846,921 68.0 
 
Black or African American Cancer Incidence 
The age-adjusted cancer incidence rates per 100,000 for the six highest elevation 
states from 2006-2014 are displayed in Table 17 for the entire Black or African American 
population in those states.  They are compared to the entire Black or African American, 
age-adjusted cancer incidence rate per 100,000 for the six lowest elevation states during 








Black or African American Bronchopulmonary Cancer Incidence, 2006-2014 
 
 
Cases Population Age-adjusted incidence rate per 
100,000  
Highest elevation states    
Colorado 697 2,219,493 50.7 
Montana 17 68,946 77.9 
New Mexico 185 519,423 54.1 
South Dakota 17 130,948 32.0 
Utah 61 379,072 50.6 
Wyoming Suppressed 75,330 Suppressed 
Totals 988 3,393,212 50.4 
Lowest elevation states    
Delaware 1,008 1,838,424 69.1 
Washington, DC 2,358 2,909,549 71.5 
Florida 11,343 28,864,160 50.7 
Louisiana 8,467 13,270,198 77.0 
Mississippi 6,141 10,022,814 76.0 
Rhode Island 266 763,987 56.5 
Totals 29,583 57,669,132 63.2 
 
Asian or Pacific Islander Cancer Incidence 
The age-adjusted cancer incidence rates per 100,000 for the six highest elevation 
states from 2006-2014 are displayed in Table 18 for the entire Asian or Pacific Islander 
population in those states.  They are compared to the entire Asian or Pacific Islander, 
age-adjusted cancer incidence rate per 100,000 for the six lowest elevation states during 








Asian or Pacific Islander Bronchopulmonary Cancer Incidence, 2006-2014 
 
 
Cases Population Age-adjusted incidence rate per 
100,000  
Highest elevation states    
Colorado 348 1,553,745 35.5 
Montana 22 76,279 44.0 
New Mexico 74 342,929 26.9 
South Dakota Suppressed 86,195 Suppressed 
Utah 122 854,164 28.9 
Wyoming Suppressed 52,930 Suppressed 
Totals 587 2,966,242 32.9 
Lowest elevation states    
Delaware Suppressed 291,937 Suppressed 
Washington, DC 49 225,590 38.5 
Florida 1,049 4,945,089 26.6 
Louisiana 182 719,583 38.1 
Mississippi 70 274,769 43.4 
Rhode Island 44 326,711 25.0 
Totals 1,453 6,783,679 28.7 
 
American Indian or Alaska Native Cancer Incidence 
The age-adjusted cancer incidence rates per 100,000 for the six highest elevation 
states from 2006-2014 are displayed in Table 19 for the entire American Indian or Alaska 
Native population in those states.  They are compared to the entire American Indian or 
Alaska Native, age-adjusted cancer incidence rate per 100,000 for the six lowest 








American Indian or Alaska Native Bronchopulmonary Cancer Incidence, 2006-2014 
 
 
Cases Population Age-adjusted incidence rate per 
100,000  
Highest elevation states    
Colorado 102 811,460 25.3 
Montana 387 625,208 111.7 
New Mexico 154 1,977,199 12.6 
South Dakota 311 693,028 101.0 
Utah 32 410,113 21.2 
Wyoming 43 142,347 55.5 
Totals 1,029 4,659,355 39.9 
Lowest elevation states    
Delaware Suppressed 56,115 Suppressed 
Washington, DC Suppressed 36,099 Suppressed 
Florida 140 899,095 20.9 
Louisiana 50 320,830 22.4 
Mississippi 23 156,072 24.5 
Rhode Island Suppressed 93,493 Suppressed 
Totals 249 1,561,704 22.7 
 
All non-White Cancer Incidence 
Since all of the data for the non-White races demonstrated no significant 
difference between the highest elevation states and the lowest elevations states, it is 
imperative that we sum up the cancer incidence data from the three races of Black or 
African American, Asian or Pacific Islander, and American Indian or Alaska Native, to 
see if the summed data still show no statistically significant difference between the 
highest elevation states and the lowest elevations states. 
The age-adjusted cancer incidence rates per 100,000 for the six highest elevation 
states from 2006-2014 are displayed in Table 20 for the entire non-White population in 
those states.  They are compared to the entire non-White, age-adjusted cancer incidence 
rate per 100,000 for the six lowest elevation states during the same period.  As it is 
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noticeable in the following table, there is no suppressed data, because of the higher 
cancer incidence statistics collected.   
Table 20 
 
All Non-White Bronchopulmonary Cancer Incidence, 2006-2014 
 
 
Cases Population Age-adjusted incidence rate per 
100,000  
Highest elevation states    
Colorado 1,147 4,584,698 41.4 
Montana 426 770,433 101.7 
New Mexico 413 2,839,551 22.0 
South Dakota 340 910,171 87.3 
Utah 215 1,643,349 30.6 
Wyoming 63 270,607 38.8 
Totals 2,604 11,018,809 41.0 
Lowest elevation states    
Delaware 1,085 2,186,476 64.1 
Washington, DC 2,411 3,171,238 69.7 
Florida 12,532 34,708,344 46.3 
Louisiana 8,699 14,310,611 74.2 
Mississippi 6,234 10,453,655 74.7 
Rhode Island 324 1,184,191 45.6 
Totals 31,285 66,014,515 58.8 
 
Data Analysis for Cancer Mortality 
The bivariate statistical technique of conducting an unpaired t-test is used for 
comparing the bronchopulmonary cancer mortality rates between highest elevation states 
and the lowest elevation states.  The Quick Calcs Online Calculator for Scientists was 
used to calculate the p-value resulting from the comparison between these two groups of 
data.   
Female Cancer Mortality 
The unpaired t-test contrasts the disparity between the female cancer mortality 
data for the highest elevation states and lowest elevation states.  The p-value is calculated 
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to be 0.0166, which by conventional criteria, indicates that there is a statistically 
significant difference between these two groups.  The female bronchopulmonary cancer 
mortality is lower in the highest elevation states than in the lowest elevation states.   
Male Cancer Mortality 
The unpaired t-test contrasts the disparity between the male cancer mortality data 
for the highest elevation states and lowest elevation states.  The p-value is calculated to 
be 0.0051, which by conventional criteria, indicates that there is a very statistically 
significant difference between these two groups.  The male bronchopulmonary cancer 
mortality is much lower in the highest elevation states than in the lowest elevation states.   
Ages 44 and Younger Cancer Mortality 
The unpaired t-test contrasts the disparity between the age 44 and younger cancer 
mortality data for the highest elevation states and lowest elevation states. The p-value is 
calculated to be 0.0006, which by conventional criteria, indicates that there is an 
extremely statistically significant difference between these two groups.  The ages 44 and 
younger bronchopulmonary cancer mortality is very much lower in the highest elevation 
states than in the lowest elevation states.    
Ages 45 to 64 Cancer Mortality 
The unpaired t-test contrasts the disparity between the age 45 to 64 cancer 
mortality data for the highest elevation states and lowest elevation states.  The p-value is 
calculated to be 0.0001, which by conventional criteria, indicates that there is an 
extremely statistically significant difference between these two groups.  The ages 45 to 
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64 bronchopulmonary cancer mortality is very much lower in the highest elevation states 
than in the lowest elevation states.    
Ages 65 and Older Cancer Mortality 
The unpaired t-test contrasts the disparity between the age 65 and older cancer 
mortality data for the highest elevation states and lowest elevation states.  The p-value is 
calculated to be 0.0244, which by conventional criteria, indicates that there is a 
statistically significant difference between these two groups.  The ages 65 and older 
bronchopulmonary cancer mortality is lower in the highest elevation states than in the 
lowest elevation states.    
White Cancer Mortality 
The unpaired t-test contrasts the disparity between the white cancer mortality data 
for the highest elevation states and lowest elevation states.  The p-value is calculated to 
be 0.0434, which by conventional criteria, indicates that there is a statistically significant 
difference between these two groups.  The white bronchopulmonary cancer mortality is 
lower in the highest elevation states than in the lowest elevation states.     
Black or African American Cancer Mortality 
The unpaired t-test contrasts the disparity between the white cancer mortality data 
for the highest elevation states and lowest elevation states.  The p-value is calculated to 
be 0.1598, which by conventional criteria, indicates that there is no statistically 
significant difference between these two groups.   
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Asian or Pacific Islander Cancer Mortality 
The unpaired t-test contrasts the disparity between the Asian or Pacific Islander 
population cancer mortality data for the highest elevation states and lowest elevation 
states. The p-value is calculated to be 0.2597, which by conventional criteria, indicates 
that there is no statistically significant difference between these two groups.   
American Indian or Alaska Native Cancer Mortality 
The unpaired t-test contrasts the disparity between the American Indian or Alaska 
Native cancer mortality data for the highest elevation states and lowest elevation states.  
The p-value is calculated to be 0.4862, which by conventional criteria, indicates that there 
is no statistically significant difference between these two groups.   
All non-White Cancer Mortality 
The unpaired t-test contrasts the disparity between the non-White cancer mortality 
data for the highest elevation states and lowest elevation states.  The p-value is calculated 
to be 0.3461, which by conventional criteria, indicates that there is no statistically 
significant difference between these two groups.  Therefore, we just reconfirmed that the 
cancer mortality data for three races of Black or African American, Asian or Pacific 
Islander, and American Indian or Alaska Native, as a group, show no statistically 
significant difference for the highest elevation states and lowest elevation states.   
Data Analysis for Cancer Incidence 
The bivariate statistical technique of conducting an unpaired t-test is used for 
comparing the bronchopulmonary cancer incidence rates between highest elevation states 
and the lowest elevation states.  The Quick Calcs Online Calculator for Scientists was 
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used to calculate the p-value resulting from the comparison between these two groups of 
data.   
Female Cancer Incidence 
The unpaired t-test contrasts the disparity between the female cancer incidence 
data for the highest elevation states and lowest elevation states.  The p-value is calculated 
to be 0.0129, which by conventional criteria, indicates that there is a statistically 
significant difference between these two groups.  The female bronchopulmonary cancer 
incidence is lower in the highest elevation states than in the lowest elevation states.   
Male Cancer Incidence 
The unpaired t-test contrasts the disparity between the male cancer incidence data 
for the highest elevation states and lowest elevation states.  The p-value is calculated to 
be 0.0019, which by conventional criteria, indicates that there is a very statistically 
significant difference between these two groups.  The male bronchopulmonary cancer 
incidence is much lower in the highest elevation states than in the lowest elevation states.   
Ages 44 and Younger Cancer Incidence 
The unpaired t-test contrasts the disparity between the age 44 and younger cancer 
incidence data for the highest elevation states and lowest elevation states.  The p-value is 
calculated to be 0.0001, which by conventional criteria, indicates that there is an 
extremely statistically significant difference between these two groups.  The ages 44 and 
younger bronchopulmonary cancer incidence is very much lower in the highest elevation 
states than in the lowest elevation states.   
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Ages 45 to 64 Cancer Incidence 
The unpaired t-test contrasts the disparity between the age 45 to 64 cancer 
incidence data for the highest elevation states and lowest elevation states.  The p-value is 
calculated to be 0.0001, which by conventional criteria, indicates that there is an 
extremely statistically significant difference between these two groups.  The ages 45 to 
64 bronchopulmonary cancer incidence is very much lower in the highest elevation states 
than in the lowest elevation states.   
Ages 65 and Older Cancer Incidence 
The unpaired t-test contrasts the disparity between the age 65 and older cancer 
incidence data for the highest elevation states and lowest elevation states.  The p-value is 
calculated to be 0.0178, which by conventional criteria, indicates that there is a 
statistically significant difference between these two groups.  The ages 65 and older 
bronchopulmonary cancer incidence is lower in the highest elevation states than in the 
lowest elevation states.    
White Cancer Incidence 
The unpaired t-test contrasts the disparity between the White cancer incidence 
data for the highest elevation states and lowest elevation states.  The p-value is calculated 
to be 0.0299, which by conventional criteria, indicates that there is a statistically 
significant difference between these two groups.  The white bronchopulmonary cancer 
incidence is lower in the highest elevation states than in the lowest elevation states.     
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Black or African American Cancer Incidence 
The unpaired t-test contrasts the disparity between the Black or African American 
cancer incidence data for the highest elevation states and lowest elevation states.  The p-
value is calculated to be 0.1286, which by conventional criteria, indicates that there is no 
statistically significant difference between these two groups.   
Asian or Pacific Islander Cancer Incidence 
The unpaired t-test contrasts the disparity between the Asian or Pacific Islander 
cancer incidence data for the highest elevation states and lowest elevation states.  The p-
value is calculated to be 0.9284, which by conventional criteria, indicates that there is no 
statistically significant difference between these two groups.   
American Indian or Alaska Native Cancer Incidence 
The unpaired t-test contrasts the disparity between the American Indian or Alaska 
Native cancer incidence data for the highest elevation states and lowest elevation states.  
The p-value is calculated to be 0.2518, which by conventional criteria, indicates that there 
is no statistically significant difference between these two groups.   
All non-White Cancer Incidence 
The unpaired t-test contrasts the disparity between the non-White cancer 
incidence data for the highest elevation states and lowest elevation states.  The p-value is 
calculated to be 0.5551, which by conventional criteria, indicates that there is no 
statistically significant difference between these two groups.  Therefore, we just 
reconfirmed that the cancer incidence data for three races of Black or African American, 
Asian or Pacific Islander, and American Indian or Alaska Native, as a group, show no 
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statistically significant difference for the highest elevation states and lowest elevation 
states.   
Summary 
In Chapter 4, I presented the findings of my research and data analyses.  I also 
describe the systematic application of my research methods.  In Chapter 5, I will 
summarize my research findings, discuss the implications for practice, explain the social 




Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
The purpose of this study was to develop the understanding of the association 
between altitude and bronchopulmonary cancer mortality and incidence by studying the 
cancer mortality data and cancer incidence data for the lowest elevation and highest 
elevation states within the United States from 2006 to 2014.  In this final chapter, I 
summarize my research findings, discuss the implications for practice, explain the social 
impact, and make recommendations for future research.    
Summary and Interpretation of Findings 
Although Hart (2011) and Simeonov & Himmelstein (2015) have pointed out 
statistically significant differences in cancer mortality and incidence between areas of 
high elevation and areas of low elevation, my findings refute their findings for certain 
races.  In the following paragraphs, I demonstrate how controlling for a possible 
confounder such as race led to my findings.  
Using CDC data from 2001 through 2005, Hart (2011) found that for the six 
lowest elevation states in the United States, the calculated age-adjusted mean cancer 
mortality rate for all cancer sites as a group was 205 cancer deaths per 100,000 people, 
and the calculated age-adjusted mean cancer mortality rate was 171 cancer deaths per 
100,000 people for the six states with the highest elevation.  These statistics demonstrated 
a statistically significant lower cancer mortality rate for the six highest elevation states 
when compared to the six lowest elevation states.  Hart did not discuss cancer incidence.   
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Simeonov and Himmelstein (2015) addressed the cancer incidence that Hart 
(2011) did not. They used 2005-2009 lung cancer incidence data from the NCI and 
demonstrated a statistically significant lower lung cancer incidence rate for areas of high 
altitude when compared to areas of low altitude.  However, Simeonov and Himmelstein 
did not discuss lung cancer mortality.   
My study was a continuation of the work that had been done by Hart (2011) and 
Simeonov and Himmelstein (2015) using new CDC data to fill the gap in the literature.  
As a result of controlling for such founders such as sex, age, and race, new findings 
emerged. The following paragraphs include detailed descriptions of my findings for the 
bronchopulmonary cancer mortality data when controlled for these three confounders.   
Female Cancer Mortality 
The p-value is 0.0166, which by conventional criteria indicates that there is a 
statistically significant difference between the highest elevation states and lowest 
elevation states.  The female bronchopulmonary cancer mortality is lower in the highest 
elevation states than in the lowest elevation states.  Results were similar for males. 
Male Cancer Mortality 
The p-value is 0.0051, which by conventional criteria indicates that there is a very 
statistically significant difference between the highest elevation states and lowest 
elevation states.  The male bronchopulmonary cancer mortality is much lower in the 
highest elevation states than in the lowest elevation states.  Both male and female results 
show lower cancer mortality among high altitude dwellers.  Therefore, gender may not be 
affecting the relationship between cancer mortality and altitude.   
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Ages 44 and Younger Cancer Mortality 
The p-value is 0.0006, which by conventional criteria indicates that there is an 
extremely statistically significant difference between the highest elevation states and 
lowest elevation states.  The ages 44 and younger bronchopulmonary cancer mortality is 
much lower in the highest elevation states than in the lowest elevation states.  This trend 
also appeared in other age groups.  
Female Ages 45 to 64 Cancer Mortality 
The p-value is 0.0001, which by conventional criteria indicates that there is an 
extremely statistically significant difference between the highest elevation states and 
lowest elevation states.  Similar to the 44 and younger group, the ages 45 to 64 
bronchopulmonary cancer mortality is much lower in the highest elevation states than in 
the lowest elevation states.  The final age group also showed similar results.  
Ages 65 and Older Cancer Mortality 
The p-value is 0.0244, which by conventional criteria indicates that there is a 
statistically significant difference between the highest elevation states and lowest 
elevation states.  The ages 65 and older bronchopulmonary cancer mortality is lower in 
the highest elevation states than in the lowest elevation states.  All three age categories 
showed lower cancer mortality among high altitude dwellers.  Therefore, age may not be 
affecting the relationship between cancer mortality and altitude.   
White Cancer Mortality 
The p-value is 0.0434, which by conventional criteria indicates that there is a 
statistically significant difference between the highest elevation states and lowest 
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elevation states.  The white bronchopulmonary cancer mortality is lower in the highest 
elevation states than in the lowest elevation states.  This coincides with the findings for 
age and gender.  
Black or African American Cancer Mortality 
The p-value is 0.1598, which by conventional criteria indicates that there is no 
statistically significant difference between the highest elevation states and lowest 
elevation states.  This was first time during the analysis of the bronchopulmonary cancer 
mortality data where I discovered a new finding.  This finding refutes the findings by 
Hart (2011) because he did not control for confounders such as race.  Thus, the 
interpretation is that for Blacks or American Americans, altitude has no influence on their 
bronchopulmonary cancer mortality.   
Asian or Pacific Islander Cancer Mortality 
The p-value is 0.2597, which by conventional criteria indicates that there is no 
statistically significant difference between the highest elevation states and lowest 
elevation states.  Thus, the interpretation is that for Asians or Pacific Islanders altitude 
has no influence on their bronchopulmonary cancer mortality.  Note that the p-value is 
slightly higher for Asian or Pacific Islander when compared to Blacks or American 
Americans.  This means that there is even less of a difference found for the Asian or 
Pacific Islander group.   
American Indian or Alaska Native Cancer Mortality 
The p-value is 0.4862, which by conventional criteria indicates that there is no 
statistically significant difference between the highest elevation states and lowest 
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elevation states.  Thus, the interpretation is that for American Indians or Alaska Natives 
altitude has no influence on their bronchopulmonary cancer mortality.  Note that the p-
value is the highest for American Indians or Alaska Natives when compared to the other 
races.  This means that there is the least amount of difference found for the American 
Indian or Alaska Native group.   
All non-White Cancer Mortality 
The p-value is 0.3461, which by conventional criteria indicates that there is no 
statistically significant difference between the highest elevation states and lowest 
elevation states.  This reconfirms that the cancer mortality data for three races of Black or 
African American, Asian or Pacific Islander, and American Indian or Alaska Native, as a 
group, show no statistically significant difference for the highest elevation states and 
lowest elevation states.  These are unique findings considering that these three groups of 
races would need to be excluded from groups that would benefit from lower 
bronchopulmonary cancer mortality at higher altitudes.   
Female Cancer Incidence 
The p-value is 0.0129, which by conventional criteria indicates that there is a 
statistically significant difference between the highest elevation states and lowest 
elevation states.  The female bronchopulmonary cancer incidence is lower in the highest 
elevation states than in the lowest elevation states.  These results coincide with the results 
for cancer mortality and are also seen in the male group for cancer incidence. 
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Male Cancer Incidence 
The p-value is 0.0019, which by conventional criteria indicates that there is a very 
statistically significant difference between the highest elevation states and lowest 
elevation states.  The male bronchopulmonary cancer incidence is much lower in the 
highest elevation states than in the lowest elevation states.  Both male and female results 
show lower cancer incidence among high altitude dwellers; therefore, like the results for 
cancer mortality, gender may not be affecting the relationship between cancer incidence 
and altitude.   
Ages 44 and Younger Cancer Incidence 
The p-value is 0.0001, which by conventional criteria indicates that there is an 
extremely statistically significant difference between the highest elevation states and 
lowest elevation states.  The ages 44 and younger bronchopulmonary cancer incidence is 
much lower in the highest elevation states than in the lowest elevation states.  Similar to 
gender, the age groups showed similar results for cancer incidence that were shown for 
cancer mortality. 
Ages 45 to 64 Cancer Incidence 
The p-value is 0.0001, which by conventional criteria indicates that there is an 
extremely statistically significant difference between the highest elevation states and 
lowest elevation states.  The ages 45 to 64 bronchopulmonary cancer incidence is much 
lower in the highest elevation states than in the lowest elevation states.  The final age 
group also showed similar results. 
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Ages 65 and Older Cancer Incidence 
The p-value is 0.0178, which by conventional criteria indicates that there is a 
statistically significant difference between the highest elevation states and lowest 
elevation states.  The ages 65 and older bronchopulmonary cancer incidence is lower in 
the highest elevation states than in the lowest elevation states.  All three age categories 
showed lower cancer incidence among high altitude dwellers.  Therefore, age may not be 
affecting the relationship between cancer incidence and altitude, which was also the case 
for cancer mortality.   
White Cancer Incidence 
The p-value is 0.0299, which by conventional criteria indicates that there is a 
statistically significant difference between the highest elevation states and lowest 
elevation states.  The white bronchopulmonary cancer incidence is lower in the highest 
elevation states than in the lowest elevation states.  This coincides with the cancer 
incidence findings for age and gender.   
Black or African American Cancer Incidence 
The p-value is 0.1286, which by conventional criteria indicates that there is no 
statistically significant difference between the highest elevation states and lowest 
elevation states.  Like cancer mortality, this was first time during the analysis of the 
bronchopulmonary cancer incidence data where I discovered a new finding.  This finding 
refutes the findings by Simeonov and Himmelstein (2015) because they did not control 
for confounders such as race.  Therefore, the interpretation is that for Blacks or American 
Americans altitude has no influence on their bronchopulmonary cancer incidence.   
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American Indian or Alaska Native Cancer Incidence 
The p-value is 0.2518, which by conventional criteria, indicates that there is no 
statistically significant difference between the highest elevation states and lowest 
elevation states.  Therefore, the interpretation is that for American Indians or Alaska 
Natives, altitude has no influence on their bronchopulmonary cancer incidence.  Note that 
the p-value is slightly higher for American Indians or Alaska Natives when compared to 
Blacks or African Americans.  This means that there is even less of a difference found for 
the American Indian or Alaska Native group.   
Asian or Pacific Islander Cancer Incidence 
The p-value is 0.9284, which by conventional criteria, indicates that there is no 
statistically significant difference between the highest elevation states and lowest 
elevation states.  Therefore, the interpretation is that for Asians or Pacific Islanders, 
altitude has no influence on their bronchopulmonary cancer incidence. Note that the p-
value is the highest for Asians or Pacific Islanders when compared to the other races.  
This means that there is the least amount of difference found for the Asian or Pacific 
Islander group.   
All non-White Cancer Incidence 
The p-value is 0.5551, which by conventional criteria, indicates that there is no 
statistically significant difference between the highest elevation states and lowest 
elevation states.  Therefore, we just reconfirmed that the cancer incidence data for three 
races of Black or African American, American Indian or Alaska Native, and Asian or 
Pacific Islander, as a group, show no statistically significant difference for the highest 
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elevation states and lowest elevation states.  These are unique findings considering that 
these three groups of races would need to be excluded from groups that would benefit 
from lower bronchopulmonary cancer incidence at higher altitudes.   
Social Impact 
The association that I had found between altitude and bronchopulmonary cancer 
incidence and mortality is for the Whites only group.  My research inquiry contributes to 
the expansion and development of a body of knowledge.  A positive social change impact 
of this study is that this study provides the groundwork for future studies to research what 
exactly in the environment is causing the differences in bronchopulmonary cancer 
mortality and incidence in the United States.   
My study does create an immediate positive social change impact through the 
very practical Bronfenbrenner’s (1977) ecological model.  The immediacy of the positive 
social change is brought about through the relevance of the individual component and 
social environment component of the ecological model.  Both the individual and social 
circles do greatly influence patterns of disease and injury.  The individual and social 
environment both strongly shape our responses to these patterns of disease and injury.   
At the individual level, the focus is on changing an individual’s knowledge and attitudes 
to influence behavior.  Social impact occurs not only when action is taken, but also when 
knowledge is learned and when attitudes are changed.  Individuals may learn of the 
information concerning lower bronchopulmonary cancer incidence and mortality at 
higher altitudes.  They may relocate to higher elevation as a prophylactic against 
bronchopulmonary cancer due to their increased awareness of this issue which may bring 
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about an immediate positive social change.  At the social environment level, interpersonal 
relationships between friends, colleagues, peers, family members, and members of the 
community influence behavior.  The immediate positive social change, through the web 
of these interpersonal networks and structures, expands and impacts even more people 
through this social arrangement and framework.     
Implication for Practice 
The main aim of this study was to develop the understanding of the association 
between altitude and bronchopulmonary cancer mortality and incidence by studying the 
cancer mortality data and cancer incidence data for the lowest elevation and highest 
elevation states within the United States from 2006 to 2014.  I have done so by observing, 
reporting, and analyzing new data from CDC WONDER.   
My study strictly focuses on the association between altitude and 
bronchopulmonary cancer incidence for new data.  It also strictly focuses on the 
association between altitude and bronchopulmonary mortality for new data.  The 
association that I had found between altitude and bronchopulmonary cancer incidence 
and mortality for the Whites only group does not imply causality, nor does it mean that 
altitude is a major influencer on bronchopulmonary cancer incidence and mortality.  
Moreover, my study does not account for lifestyle (such as tobacco use), nor does my 
study account for higher population densities, which lead to increased air pollution due to 
increased use of motor vehicles, watercrafts, and aircrafts.  
The theoretical framework for my study is the ecological model. The tenets of the 
ecological model are depicted by the four levels of influence used in this model, and they 
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serve as the four central components of this framework.  They are the individual level, 
social environment, physical environment, and public policy components.    
At the public policy level, the focus is on changing policy to influence behavior.  
Public health strategies may be implemented to increase awareness and understanding of 
the association between altitude and bronchopulmonary mortality and incidence.  
Without the implementation of public health strategies, it may be difficult to witness the 
power and impact of the ecological model.  Government agencies can promote and 
distribute my novel finding of the beneficial outcomes for bronchopulmonary cancer 
mortality and incidence via public health announcements on television, radio, and the 
internet.  The target audience would be only for the Whites only population of the United 
States.  At the same time, these policies and promotions should remind the target 
audience of the responsibility to live healthy lifestyles such as avoiding tobacco.  These 
policies and promotions encouraging relocation for Whites to higher altitudes would then 
have a better chance to succeed and lead to positive health outcomes.   
Recommendations for Future Research 
I believe my study has paved the way for an expanded research into collecting 
bronchopulmonary cancer mortality and cancer incidence for all 50 states.  My study 
advances opportunities for future research for concept validation and theory 
reinforcement.  More research will be needed to refine and build up on my novel 
findings.  This next phase of research is important because we can rank the various states 
according to their mean elevations. We can then plot each state’s bronchopulmonary 
cancer mortality data against the mean elevation of each state.  The data for each state 
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should be controlled for age, sex, and race as well just as I had done in my study for the 
six highest and the six lowest elevation states.  There will be 51 data points (including the 
District of Columbia) for each of the myriads of graphs that can be generated from 
controlling for age, sex, and race.  A linear regression analysis can then be done to see 
how well the data fits the model.  It would be very misleading to do a linear regression fit 
for the data that I had studied on bronchopulmonary cancer mortality because my data 
only dealt with the extremes, i.e., my data only dealt with the 6 highest elevation states 
and the 6 lowest elevation states.  
We can also plot each state’s bronchopulmonary cancer incidence data against the 
mean elevation of that state.  The data for each state should be controlled for age, sex, 
and race as well just as I had done in my study for the six highest and the six lowest 
elevation states.  There will be 51 data points (including the District of Columbia) for 
each of the myriads of graphs that can be generated from controlling for age, sex, and 
race.  A linear regression analysis can then be done to see how well the data fits the 
model.  It would also be very misleading to do a linear regression fit for the data that I 
had studied on bronchopulmonary cancer incidence because my data only dealt with the 
extremes, i.e., my data only dealt with the 6 highest elevation states and the 6 lowest 
elevation states.  
My study has also paved the way for future research to find out the reasons 
behind why the three races, Black or African American, Asian or Pacific Islander, and 
American Indian or Alaska Native, show no statistically significant difference in 
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bronchopulmonary cancer mortality and cancer incidence for the highest elevation states 
and lowest elevation states.   
Conclusion 
In this final chapter, I summarized my research findings, discussed the 
implications for practice, explained the social impact, and made recommendations for 
future research. This study provides the groundwork for future studies to research what 
exactly in the environment is lowering the bronchopulmonary cancer mortality and 
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